Peter M Voorhees

Jul 7, 2024 | nature.com | Ajai Chari |Jonathan Kaufman |Jacob P. Laubach |Brandi N. Reeves |Luciano Costa |Sarah A Holstein | +4 more

AbstractThe randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities (HRCAs) per revised definition (del[17p], t[4;14], t[14;16], t[14;20], and/or gain/amp[1q21]).

Jan 25, 2024 | targetedonc.com | Peter M Voorhees

In this Precision Medicine Perspectives series, “Evaluating Treatment Outcomes in Newly Diagnosed Multiple Myeloma,” Peter Voorhees, MD, at the Levine Cancer Institute in Charlotte, NC, outlines the therapeutic landscape of newly diagnosed multiple myeloma and explores how recent data will shape treatment paradigms. Targeted Oncology™: Regarding treatment selection in newly diagnosed multiple myeloma, what factors guide your selection for induction maintenance and consolidation therapy?

Dec 21, 2023 | targetedonc.com | Peter M Voorhees

Current and Emerging Standard of Care in NDMMExpert insights into the evolving therapeutic landscape for newly diagnosed multiple myeloma, highlighting transplant eligibility, combination regimens, and emerging data.

Oct 18, 2023 | newsbreak.com | Peter M Voorhees

This site uses various technologies, including third-party cookies, pixels, and codes, to personalize our website functionalities, measure website usage and performance and provide targeting advertising. Information about your site visit may be stored or shared with third parties as identified in our Privacy Policy. By continuing to use this website you consent to our Privacy Policy and Terms of Use.

Sep 11, 2023 | thelancet.com | Peter M Voorhees |Douglas Sborov |Jacob P. Laubach |Jonathan Kaufman

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.